Report Detail

Pharma & Healthcare Otitis Media - Pipeline Review, H1 2019

  • RnM2890047
  • |
  • 06 February, 2019
  • |
  • Global
  • |
  • 60 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Otitis Media - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2019, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Otitis Media - Overview

              Otitis Media - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Otitis Media - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Otitis Media - Companies Involved in Therapeutics Development

                                      Lee's Pharmaceutical Holdings Ltd

                                        Madam Therapeutics BV

                                          Merck & Co Inc

                                            MerLion Pharmaceuticals Pte Ltd

                                              Novus Therapeutics Inc

                                                Yuhan Corp

                                                  Otitis Media - Drug Profiles

                                                    (cholesteryl palmitate + colfosceril palmitate) - Drug Profile

                                                      Product Description

                                                        Mechanism Of Action

                                                          R&D Progress

                                                            (dexamethasone + piperacillin + tazobactam) - Drug Profile

                                                              Product Description

                                                                Mechanism Of Action

                                                                  R&D Progress

                                                                    finafloxacin - Drug Profile

                                                                      Product Description

                                                                        Mechanism Of Action

                                                                          R&D Progress

                                                                            pazufloxacin - Drug Profile

                                                                              Product Description

                                                                                Mechanism Of Action

                                                                                  R&D Progress

                                                                                    PCL-1440 - Drug Profile

                                                                                      Product Description

                                                                                        Mechanism Of Action

                                                                                          R&D Progress

                                                                                            pneumococcal (13-valent) vaccine - Drug Profile

                                                                                              Product Description

                                                                                                Mechanism Of Action

                                                                                                  R&D Progress

                                                                                                    pneumococcal (23-valent) vaccine - Drug Profile

                                                                                                      Product Description

                                                                                                        Mechanism Of Action

                                                                                                          R&D Progress

                                                                                                            Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile

                                                                                                              Product Description

                                                                                                                Mechanism Of Action

                                                                                                                  R&D Progress

                                                                                                                    Small Molecules for Otitis Media - Drug Profile

                                                                                                                      Product Description

                                                                                                                        Mechanism Of Action

                                                                                                                          R&D Progress

                                                                                                                            solithromycin - Drug Profile

                                                                                                                              Product Description

                                                                                                                                Mechanism Of Action

                                                                                                                                  R&D Progress

                                                                                                                                    Otitis Media - Dormant Projects

                                                                                                                                      Otitis Media - Product Development Milestones

                                                                                                                                        Featured News & Press Releases

                                                                                                                                          Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

                                                                                                                                            Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201

                                                                                                                                              Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board

                                                                                                                                                Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201

                                                                                                                                                  Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

                                                                                                                                                    Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

                                                                                                                                                      Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections

                                                                                                                                                        Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media

                                                                                                                                                          Appendix

                                                                                                                                                            Methodology

                                                                                                                                                              Coverage

                                                                                                                                                                Secondary Research

                                                                                                                                                                  Primary Research

                                                                                                                                                                    Expert Panel Validation

                                                                                                                                                                      Contact Us

                                                                                                                                                                        Disclaimer

                                                                                                                                                                        Summary:
                                                                                                                                                                        Get latest Market Research Reports on Otitis Media. Industry analysis & Market Report on Otitis Media is a syndicated market report, published as Otitis Media - Pipeline Review, H1 2019. It is complete Research Study and Industry Analysis of Otitis Media market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                        Last updated on

                                                                                                                                                                        REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                        Purchase this Report

                                                                                                                                                                        $2,000.00
                                                                                                                                                                        $4,000.00
                                                                                                                                                                        $6,000.00
                                                                                                                                                                        1,606.00
                                                                                                                                                                        3,212.00
                                                                                                                                                                        4,818.00
                                                                                                                                                                        1,878.00
                                                                                                                                                                        3,756.00
                                                                                                                                                                        5,634.00
                                                                                                                                                                        309,080.00
                                                                                                                                                                        618,160.00
                                                                                                                                                                        927,240.00
                                                                                                                                                                        167,160.00
                                                                                                                                                                        334,320.00
                                                                                                                                                                        501,480.00
                                                                                                                                                                        Credit card Logo

                                                                                                                                                                        Related Reports


                                                                                                                                                                        Reason to Buy

                                                                                                                                                                        Request for Sample of this report